Articles tagged with Target Proteins
A new report recommends that researchers use expert reviews and computational Big Data approaches to select high-quality chemical probes. The report highlights the value of resources like the Chemical Probes Portal, which provides assessments on 192 chemical probes for 181 different proteins of interest.
Researchers have discovered a way to stop the rabies virus from shutting down the immune system, solving a long-standing scientific puzzle. The breakthrough involves disabling the binding of viral proteins to host cells' STAT1 protein, paving the way for new oral vaccines.
Researchers at the University of Zurich have discovered a new family of synthetic antibiotics that target essential outer membrane proteins in Gram-negative bacteria, disrupting their synthesis and leading to cell bursting.
Researchers developed optogenetic platform 'optobody' that activates antibody fragments with blue light, enabling temporal control over protein functions in living cells. The tool has great clinical promise for therapeutic strategies in cancer and inflammatory diseases.
Scientists identified a molecular pathway that contributes to PAH's development, targeting the EYA3 protein for new therapies. Blocking this protein prevents dangerous lung artery thickening and reversal of vascular remodeling was seen in laboratory rat models.
Despite three failed replications, Science is maintaining an Editorial Expression of Concern (EEoC) on the 2016 study by Siddappa N. Byrareddy et al., which reported significant results for SIV virus treatment using an antibody targeting integrin protein α4β7.
Researchers identified central UPS regulators as essential for degrader efficacy, and found modulator gene-networks that can inform patient stratification. The study provides new insights into the rational design of small-molecule degraders.
The study identified a novel protein interface in the polymerase complex that is pivotal for regulating polymerase activity, providing a new objective for target-based antiviral drug discovery. The findings reveal a vulnerability in the viral genome that could be exploited as a target for small-molecule antiviral drugs.
A team at Harvard's Wyss Institute developed Immuno-SABER, a DNA-based signal amplification method that allows for the multiplexed visualization of many proteins in single cells. The approach enables independent tuning of signal intensity and simultaneous detection of multiple proteins with high sensitivity and speed.
Researchers developed a new method to analyze nanoparticles' movements in real-time, finding that targeting nanostars rotate faster and move across larger areas than non-targeting counterparts. This technology holds promise for reducing side effects of cancer treatments by delivering drugs directly to diseased cells.
Scientists have discovered a crucial protective role of Polo-like kinase (PLK1) in guarding against severe DNA damage during cell division. PLK1 is essential for maintaining chromosome rigidity and preventing chromosome rearrangements that can lead to cancers.
A new CRISPR platform, RESCUE, has been developed to target RNA edits that were not previously possible. The system allows for precise modifications of cytosine bases in RNA transcripts, enabling the treatment of devastating diseases affecting the brain.
A study by NUS researchers found a close association between liposarcoma and the bromodomain and extraterminal (BET) protein family. The development of LPS is highly dependent on the presence of BET proteins, making them a promising cancer target for treatment.
A team from TUM has successfully marked proteins with ubiquitin in a targeted manner, paving the way for exploring the inner workings of this vital regulatory system. The discovery may lead to a better understanding of protein function and its impact on diseases such as cancer and neurodegenerative disorders.
Researchers at Arizona State University have developed a method to assemble protein and DNA building blocks into three-dimensional cages. The technique allows for precise control over cage structure and size, opening up new possibilities for targeted delivery, structural biology, biomedicine, and catalytic materials.
A Yale team isolated antibodies from mice bitten by mosquitoes and found a protein, AgBR1, that exacerbates Zika infection. Blocking this protein with an antiserum reduced Zika virus levels and provided partial protection in infected mice.
Researchers have developed a strategy to create new small-molecule drugs by reprogramming rapamycin. A library of 45,000 altered molecules was screened to identify a new compound, rapadocin, that inhibits cellular nucleoside uptake without toxicity. Rapadocin targets ENT1 protein and shows promise for treating kidney injury.
A team of researchers at the University of Pittsburgh has developed a method to trap the pathological protein TDP-43, which is linked to 97% of amyotrophic lateral sclerosis cases. An oligonucleotide-based approach prevents TDP-43 aggregation and rescues neurons from neurodegeneration.
Researchers at UNIST developed a novel targeted drug delivery system using protein corona shield, achieving 10 times greater therapeutic efficacy in preventing unwanted protein adsorption. The system demonstrated lower toxicity and excellent tumor-targeting ability in mouse models of cancer.
A promising compound TTP399 targets glucokinase protein implicated in type 2 diabetes, improving glycemic control and reducing liver fat. Phase 2 clinical trial of 190 participants shows no adverse effects, paving way for potential new treatment options.
Researchers at the University of Alberta have identified a potential new treatment for ALS by repurposing an existing medication called telbivudine. The drug targets the toxic properties of SOD1, a misfolding protein that causes toxicity in patients with ALS.
A new study assesses the reliability of CETSA HT for early drug discovery, demonstrating good correlations with other assay formats. The technology highlights different compound responses, providing a better understanding of cellular effects.
The study provides new insights into targeting the human T-cell immunoglobulin and mucin domain containing protein-3 (hTIM-3) for treating various cancers. The high-resolution structure of hTIM-3 will help develop useful therapeutics.
Scientists have developed an antibody that blocks the inflammatory and oxidative activity of fibrin, a blood protein that contributes to neurodegeneration in the brain. The treatment has shown promise in reducing inflammation and neurodegeneration in both mouse models of multiple sclerosis and Alzheimer's disease.
A stage four sarcomatoid kidney cancer patient has achieved complete response to immunotherapy treatment, marking a significant breakthrough in the fight against this aggressive form of cancer. Researchers are now recruiting patients with sarcomatoid kidney cancer in clinical trials with checkpoint inhibitors.
Researchers at the University of Washington School of Medicine have successfully created a novel, de novo-designed beta-barrel protein that can bind to specific small molecules. The achievement paves the way for custom-designed proteins with precise affinity and functionality.
The FAT10 protein has a unique structure with two domains and a flexible linker, allowing it to regulate degradation in an efficient manner. This finding has significant implications for potential cancer therapies, as FAT10's presence is associated with aggressive tumor growth.
Researchers at Ruhr-University Bochum developed a new infrared sensor method to analyze the structure of proteins affected by active agents. This method provides rapid measurements, allowing for the detection of structural changes within minutes and the identification of binding periods that determine drug efficacy.
Researchers at the University of Adelaide have designed a new molecule that successfully targets PCNA, a protein essential for DNA replication in rapidly dividing cancer cells. The molecule shows increased potency over existing PCNA inhibitors and is likely to cause fewer side effects.
A recent Penn Medicine study found that nearly all major neurodegenerative diseases share common 'proteinopathies' present in varying degrees across different diseases, expanding the potential for combination therapy targeting multiple disease proteins.
Fragment-based lead discovery (FBLD) increases the chances of finding hit compounds and delivers results without high-throughput screening investment. FBLD starts by identifying low molecular weight fragments that bind to protein targets, then grows them into potent drug candidates.
A study found that aggressive mice showed increased dominance and aggression when ΔFosB was overexpressed, suggesting a link between this protein and violent behavior. The research suggests targeting ΔFosB may reduce aggression by modifying the brain's reward system.
Researchers have identified a critical aspect of healthy cell division and revealed how a vital protein called CENP-A is incorporated into chromosomes. A two-step process was found to be essential for replenishing the protein, involving targeting and transcription-induced remodelling of chromatin.
Researchers discovered a small molecule that destroys HIV protein Tat, which is responsible for revving up the virus. The molecule reveals proteins in host cells that can potentially target Tat and halt its replication process. This finding offers new insights into the biology of HIV and potential targets for therapy.
New research from UEA reveals that targeting Beta3-integrin in combination with microtubule-targeting agents can effectively slow tumour growth and reduce side effects. This approach could lead to a re-purposing of existing chemotherapies to stop tumours recruiting blood supply.
Antibodies against myeloperoxidase signal impending relapse in antineutrophil cytoplasmic antibody-associated vasculitis patients. Routine monitoring may help prevent disease flare-ups.
A study by University of Warwick and Manchester researchers reveals that small rises in temperature speed up a cellular 'clock' controlling the response to infections. This new understanding could lead to more effective drugs targeting A20 protein, which regulates inflammation.
A study published in the Journal of Experimental Medicine found that a signaling protein called interleukin-1 receptor accessory protein (IL1RAP) plays a critical role in driving the development and progression of acute myeloid leukemia. IL1RAP amplifies multiple key pathways, making it a promising target for treatment.
Researchers have developed a molecule that can block multiple strains of the common cold virus from hijacking human cells. The molecule targets N-myristoyltransferase, a protein in human cells, making emergence of resistant viruses highly unlikely.
Researchers at Duke University have developed a technique to capture RNA molecules in precise images, revealing new opportunities for drug discovery. The method identifies potential anti-HIV compounds from millions of possibilities, showcasing its accuracy and potential to treat various ailments.
Researchers at EPFL have developed a new peptide format called double-bridged peptides that can bind to any disease target with high affinity and stability. By creating an enormous diversity of peptide architectures, they were able to isolate high-affinity binders to important protein targets, including kallikrein and interleukin-17.
Researchers have developed a process for creating ultrathin, self-assembling sheets of synthetic materials that can function like designer flypaper in selectively binding with viruses, bacteria, and other pathogens. The sugar-coated nanosheets are made from bio-inspired polymers known as peptoids and can effectively mimic cell surfaces.
Researchers developed a high-throughput imaging-based approach to investigate protein stability, identifying previously unknown human proteins targeted by HIV. The platform has broad applications in diseases such as Alzheimer's, cancer, and autoimmune disorders.
Researchers identified four new antibodies that bind to RSV's F protein, inhibiting the virus's ability to fuse with human cells. These findings could aid in vaccine development for two major viruses: RSV and its close relative hMPV.
Cancer researchers have developed a new approach to target 'undruggable' cancer-causing genes by attacking the proteins they produce on the cell surface. The study reveals that antibodies against specific proteins can deliver cytotoxic or immunotherapeutic compounds to Ras-mutant cancer cells.
A study published in PLOS ONE found that double-stranded RNA (dsRNA) treatment can reduce the fertility of adult house flies by interfering with gene expression. The treatment, which targets specific genes involved in the fly's reproductive process, resulted in reduced egg development and oviposition rates.
Researchers at Duke University Medical Center are using drug discovery methods that have fueled cancer breakthroughs to identify alternatives to antibiotics for Lyme disease and other tick-borne illnesses. By targeting vulnerable areas of disease-causing bacteria, they aim to develop new therapies that spare the normal gut microbiome.
Researchers at Osaka University developed a new strategy for multiple myeloma immunotherapy by identifying a novel therapeutic target, MMG49, specifically recognizing integrin β7. The resulting CAR-T treatment showed anti-MM effects without damaging normal blood cells.
Rice University scientists invented a bifunctional recognition system called NanoDeg to target specific proteins and regulate their degradation. This plug-and-play system allows for precise control over protein expression levels, enabling the study of cellular dynamics and synthetic gene circuits.
A multidisciplinary research collaboration has found a way to target key cancer-linked proteins by exploiting a unique binding site in an enzyme. The approach could lead to the development of new drugs that control tumour growth and promote normal cell control mechanisms.
Researchers created a computational model to improve the efficiency of CRISPR-Cas9 genome editing by allowing off-target cuts, which may help on-target cutting be faster. The model suggests that proteins can correct mistakes and tolerate minor mutations, potentially leading to more precise gene editing.
Researchers used computational drug discovery and in vitro enzyme assays to identify potential therapeutic protein inhibitors for Chagas disease. The study successfully selected four drug-like compounds that interacted with a key amino acid, demonstrating the promise of docking simulation for identifying effective treatments.
Researchers identify REC3 domain as a master controller of DNA cutting and engineer mutations to improve accuracy without impacting efficiency. The hyper-accurate gene editor, dubbed HypaCas9, retains on-target efficiency while discriminating between on- and off-target sites in human cells.
Researchers have obtained the highest resolution map yet of human proteins critical to DNA function, providing insights into gene research and drug development. The study used cryo-electron microscopy to resolve the structure of transcription factor IIH at near-atomic resolution.
Scientists have discovered that ribosomes, the tiny factories of cells that produce proteins, are attached to mitochondria. This finding provides new insights into the process of protein targeting and mitochondrial function, which is essential for understanding diseases such as Parkinson's.
Researchers have designed a new kind of antibody that targets toxic protein structures common to Alzheimer's disease, Parkinson's disease, and related conditions. The study demonstrates the effectiveness of these antibodies in removing toxic forms without triggering immune toxicity.
A USC researcher has identified a novel protein variant that can be targeted to prevent the human immunodeficiency virus from harming HIV-positive individuals. This approach differs from traditional methods of targeting viruses and may offer a more effective solution to treating acute HIV infection.
Researchers at NC State University have developed a high-throughput technique that can determine the potential toxicity of chemicals in seconds, enabling prioritization for in-depth testing. This approach accelerates the identification of environmentally hazardous chemicals and could significantly expedite screening.
Researchers have developed a simple methodology to capture proteins implicated in Alzheimer's disease and other conditions. The new method uses engineered tails to trap sugar-modified proteins, which can then be identified using routine laboratory techniques.
Researchers at the University of Cambridge have designed antibodies to stop the production of protein deposits linked to Alzheimer's disease. The antibodies, developed using computer-based methods, were tested in test tubes and nematode worms, showing almost complete elimination of toxic pathogens.